Attractive numbers on paper do not always translate into compelling investments, and three FTSE 100 income stocks illustrate that point sharply heading into 2027.
GSK trades at just 9.8 times next year’s forecast earnings, a discount that might ordinarily draw income hunters into the stock without much further scrutiny.
Yet the pharmaceutical giant has a persistent habit of underperforming the broader FTSE 100, and its dividend yield of 3.7% sits only marginally above the index average.
Management has set an ambitious target of surpassing £40bn in annual revenue by 2031, compared with £32.7bn recorded last year, but the market has so far declined to reward that ambition with a higher valuation.
A more fundamental concern is the looming expiry of key patents within GSK’s HIV franchise, with several due to lapse before 2029, removing a significant source of earnings protection at a critical moment.
Haleon presents a different but equally frustrating picture for income-focused investors, with the consumer healthcare group delivering a yield of just 2.1% despite operating in an exceptionally mature market.
The company, whose portfolio includes household names such as Sensodyne, Panadol and Beechams, posted third-quarter organic revenue growth of 2.6%, falling short of analyst expectations due to weakness in cough, cold and flu categories.
Full-year revenue growth is now expected to come in at roughly 2.5%, well below the company’s own medium-term target range of 4% to 6%, leaving little justification for accepting such a modest income return.
There was a bright spot in emerging markets, particularly India, where high-teens growth was recorded during the quarter, but that alone cannot compensate for the mismatch between sluggish overall growth and an underwhelming yield.
Of the three stocks, Ithaca Energy carries what looks at first glance like the most tempting proposition, boasting the highest dividend yield in the entire FTSE 100 at 9.5% for 2026.
The company allocates 30% of its post-tax operating cash flow to dividends and has hedging arrangements on oil and gas prices extending through to 2028, providing some near-term income visibility.
Ithaca also holds a 20% stake in the Rosebank oil field in the UK North Sea, a development that could represent meaningful long-term growth if it clears regulatory hurdles.
That approval is far from guaranteed, however, with up to 100 MPs, predominantly from the Labour benches, reportedly prepared to oppose the project’s advancement.
Reports also indicate that the energy secretary is currently minded to reject the Rosebank development, a stance that would remove a significant pillar of the investment case at a stroke.
With the Iran conflict reportedly drawing to a close, the conditions that drove oil prices higher this year look less likely to persist, adding further uncertainty to an already complex picture for the North Sea producer.
A 9.5% yield can mask considerable risk, and in Ithaca’s case the combination of commodity price exposure, political opposition and regulatory uncertainty makes that income stream far less dependable than the headline figure suggests.
Investors hunting for reliable FTSE 100 income heading into 2027 may find that the most eye-catching yields and the lowest valuations come bundled with the most uncomfortable questions.

